A method that increases the sensitivity and specificity of the direct agglutination (AG) test for diagnosis of Toxoplasma gondii infection is described. Qualitative results in the Sabin-Feldman dye test (DT) and AG test were in excellent agreement (98%). Differences in titers between these two tests often related to the length of time the individual was infected. The AG test titer was most often lower than the DT titer during acute (recent) infection; the AG test titer was most often higher than the DT titer in older or chronic infection. If the AG test antigen described here can be made available, the AG test would be ideal for use as a screening test and would provide a simple and inexpensive means for the surveillance of seronegative women during pregnancy and for detection of sero-conversions.
A method that increases the sensitivity and specificity of the direct agglutination (AG) test for diagnosis of Toxoplasma gondii infection is described. Qualitative results in the Sabin-Feldman dye test (DT) and AG test were in excellent agreement (98%). Differences in titers between these two tests often related to the length of time the individual was infected. The AG test titer was most often lower than the DT titer during acute (recent) infection; the AG test titer was most often higher than the DT titer in older or chronic infection. If the AG test antigen described here can be made available, the AG test would be ideal for use as a screening test and would provide a simple and inexpensive means for the surveillance of seronegative women during pregnancy and for detection of sero- conversions.
At present, the diagnosis of acute acquired infection with Toxoplasma gondii depends on serological test results. A number of problems associated with available methods for serodiagnosis of this infection have been an impetus to search for alternative methods. The routine methods presently available to physicians in practice are often expensive to perform, time consuming, not readily adaptable to screening programs, or not sensitive enough to be useful in early diagnosis of the infection (e.g., the hemagglutination test).
The toxoplasma agglutination (AG) test was first described by Fulton et al. (5) (6) (7) (8) . This method uses whole killed organisms and is now routinely performed in France with an antigen that has been prepared as described by Ardoin et al. (1) and that is commercially available (bioM6rieux, Charbonnieres-les-Bains, France). The method is very simple and useful but as presently used has two drawbacks. First, it lacks sensitivity; the titer in the AG test is usually much lower than that in the dye test (DT) or the conventional immunofluorescent-antibody (IFA) test. As a consequence, some sera that are positive in the latter two tests are reported as negative in the AG test. Second, it lacks specificity; some sera that are negative in the DT and IFA test are reported as positive in the AG test (2) . This has been shown to be due to the binding of normal immunoglobulin M (IgM) ("natural IgM antibody") to the surface of the parasite (3) .
We describe here a method for preparing antigen which increases the sensitivity of the AG test and a method for suppressing nonspecific agglutination by the use of a buffer containing 2-mercaptoethanol (2ME). When the AG test is modified by these two methods, its specificity and sensitivity parallel those of the DT. The technique and the reading are so simple and accurate that, if the antigen is made available, the modified AG test method would be convenient for laboratories that perform serology only occasionally as well as for those that perform large-scale surveys.
MATERIALS AND METHODS
Preparation of the antigen. The antigen is prepared using the RH strain of toxoplasma cultivated along with mouse TG 180 sarcoma cells in the peritoneal cavities of mice. As many as 2 x iO8 to 5 x 108 toxoplasma per mouse may be obtained with this method. This is approximately 10 The sediment of the pooled stage IV and V exudates is resuspended in phosphate-buffered saline, pH 7.2 (PBS), containing 0.05% trypsin and incubated in a water bath at 37°C under continuous agitation. Portions are examined microscopically every 5 min for the disruption of cells. As soon as the cells are disrupted, the suspension of parasites is centrifuged for 10 min at 500 to 600 x g, the supernatant is discarded, and the sedimented parasites are resuspended in PBS and centrifuged again. After the second centrifugation, parasites are suspended in Formalin that has been diluted 1:5 in PBS (6% formaldehyde solution). The parasites are kept overnight in Formalin. The following day (at least 16 h after suspension in Formalin), they are centrifuged and resuspended in PBS. The sediment is washed in PBS three times to remove both cell debris and the formaldehyde. The parasites are then suspended in an alkaline buffer (pH 8.7) which contains 7 .02 g of NaCl, 3 .09 g of H3BO3, 24 ml of 1 N NaOH, 4 g of bovine plasma albumin (fraction V), and enough distilled water to bring the volume to 1 liter. (This formula is also used as the alkaline buffer in the hemagglutination inhibition test for rubella antibodies, which is commercially available. In the hemagglutination kits, it is recommended that the buffer be adjusted to pH 9, but it is usually pH 8.7.) Sodium azide (0.1%) is added as preservative.
The concentration of Formalin is important. Parasites should retain their normal crescentic shape. When insufficiently fixed, a less sensitive antigen is obtained.
The pH is critical for obtaining a reliable AG test. Spontaneous agglutination (sedimentation as a carpet) occurs when the pH is acid. The final pH in the wells should be slightly greater than 8 The results of 100 consecutive examinations of the same positive control serum are shown in Table 4 . The mean titer in the DT was 1:10,600, with no result greater than 1:25,600 or less than 1:3,200. The mean titer in the AG test was 1: 13,810, with no result greater than 1:25,600 or less than 1:3,200. The results (in twofold dilutions) of the DT and AG test in 1,000 sera that were positive at 1:800 in the screening test are shown in Table 5 , and results of 1,000 sera that were positive at 1:20 and negative at 1:800 in the screening test are shown in Table 6 . In Table 7 are the results obtained in sera from 200 selected cases of recent acute infection. These samples were either the first positive sera obtained from pregnant women with previously negative serology who were routinely tested every month or the results of sera drawn from patients with clinical toxoplasmosis in whom the second sample of serum taken at a later date showed a significant increase in titer.
Studies in Palo Alto. Sera tested in these studies were chosen at random from groups of sera found to be negative or positive at various titers in the DT. In addition, sera from known cases of chronic infection and from cases of acute toxoplasmosis were used; these sera were obtained from a bank of specimens kept in the Palo Alto laboratory. To improve upon this potentially valuable method, the method of antigen preparation described in this report was developed. In attempts to increase the sensitivity of the antigen, it became evident that false-positive reactions are not the exception but the rule; positive results are obtained in the AG test with every serum from normal adults as well as with serum taken from normal infants as early as 6 to 12 months of age (3) . The false-positive titer may be high, frequently greater than 1:100 and sometimes 1: 1,000 or more. It has previously been shown (3) that this agglutination is due to the binding of "normal" IgM to the surface of the organisms (a phenomenon that is also responsible for the polar staining observed when performing the IFA test [9, 12] ). Ablation of IgM activity by the use of 0.2 M 2ME diluted in PBS as a diluent in all the reaction wells proved an effective means of eliminating false-positive reactions. The fact that specific IgM antibodies are inhibited by 2ME is not of practical importance; when present, they are demonstrable in the IgM-IFA test, which should be performed in sera that are positive in the conventional IFA test, DT, or AG test. It has been suggested that the difference in AG test titer before and after 2ME treatment can be used as evidence for the presence of IgM antibody. This method does not allow one to differentiate between agglutination due to "normal" IgM or to "specific" IgM, or to rheumatoid factor, and thus it is not reliable for this purpose.
The AG test is slightly more sensitive than the DT (Table 3) , but the two tests are in the same range (approximately 0.1 IU/ml). The tests are equally reproducible (Table 4) . Thus, differences in titers observed in individual sera cannot be explained solely by differences in sensitivity of the test, by lack of reproducibility, or by lack of accuracy in dilutions. In some sera, the titer in the DT is higher than that in the AG test, whereas the reverse is observed in many sera. These differences suggest that DT 
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Differences in the evolution of the DT and AG test antibodies partly explain the discrepancies observed in the screening test (when sera are tested at 1:20 and 1:800). When the discrepancy is a positive DT and negative AG test, in most cases the IgM-IFA test will be positive. This discrepancy is observed in samples obtained during the early days of the infection. The reverse discrepancy (AG test is positive and DT is negative) is most often related to the slight difference in sensitivity of the two tests; in many of these sera, the DT proves to be positive at a dilution of 1:5 or 1:10. But other causes are possible for these discrepancies. For instance, inhibition of complement due to bacterial contamination of the serum sample or to a high anticomplementary activity may lead to a falsenegative DT. In a few sera, we felt that the 2ME concentration may have been too low to completely inactivate the effect of the normal IgM at a dilution of 1:20. Finally, in two cases (among 600,000 sera), we have observed a high titer in the AG and IgG-IFA tests, whereas the DT and complement fixation test were negative; this suggested that the IgG antibodies in these two patients might be ofrestricted heterogeneity and might belong only to the subclass 4 of IgG.
Premarital examination of women for toxoplasmosis is now compulsory in France, and pregnant women with a negative test at the beginning of their pregnancy are further examined every 1 or 2 months up to the time of delivery. To better control the large series of tests that must be performed, it became necessary to perform the serological tests in double series. This is why the modified AG method was introduced as a routine test in one of our laboratories (that of G.D. in Paris) in 1974. During the subsequent 6 years it has proved so simple, useful, and reliable that we felt it would be of interest to others involved in toxoplasma serology.
Since agreement of the AG test with the DT is close to 99%, it would be ideal for use as a screening test for identifying seronegative patients in a population of pregnant women in countries in which the percentage of positive individuals in the age group being screened is relatively low (e.g., United States). This would allow for a rapid and a simple selection of those women who are seropositive and who should be further examined by other serological methods (13; C. B. Wilson and J. S. Remington, submitted for publication). This would also provide a very simple and inexpensive means for the surveillance of seronegative women during pregnancy and for the detection of seroconversions.
